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Abstract 
Aim: Short-time models (STM) to study the cardiotoxicity (acute or chronic) of doxorubicin 
in rats are of interest to assess protective interventions and pathways. STM promotes more 
ethical animal treatment with less stress, and at a lower cost compared to established long-
time models (LTM). We wanted to investigate if a STM of 9 days yields the same information 
regarding cardiotoxicity as a LTM of 9 weeks. 
Methods: Male Wistar rats received identical drug administration protocols in STM and LTM. 
The two intervention groups (n = 6) received intraperitoneal (i.p.) injections of 2mg/kg 
doxorubicin every day on 5 consecutive days, with a total cumulative dose of 10mg/kg. The 
two control groups (n = 6), received an equivalent volume of saline injected every day on 5 
consecutive days. Hearts from STM and LTM were excised and Langendorff-perfused after 9 
days or 9 weeks, respectively, after the first drug injection. Cardiotoxicity was assessed in 
paced Langendorff hearts by release of hydrogenperoxide (H2O2) and troponin T (TnT) in 
effluent, by myocardial accumulation of doxorubicin and its metabolite doxorubicinol, and by 
physiological parameters recorded during pressure, or volume regulated perfusion. 
Results: In STM, hearts exposed to doxorubicin demonstrated a 15% reduction in left 
ventricular developed pressure (LVDP) irrespective of flow mode, and a 13% increase in 
aortic pressure (AoP), during volume regulated perfusion, an index of coronary resistance, 
compared to controls. Left ventricular end-diastolic pressure (LVEDP) was increased 72% 
during pressure regulated perfusion and 100% during volume regulated perfusion in STM. In 
LTM, hearts exposed to doxorubicin demonstrated a 40% reduction in LVDP during pressure 
regulated perfusion and a 20% reduction during volume regulated perfusion. LVEDP was 
70% higher in doxorubicin treated hearts during pressure regulated perfusion and 80% higher 
during volume regulated perfusion. In addition, aortic pressure was increased 30% during 
volume regulated perfusion. In both STM and LTM, hearts exposed to doxorubicin 
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demonstrated a higher H2O2 and TnT release, compared to respective controls. The difference 
was most pronounced in STM. Myocardial content of doxorubicin was detectable in both 
STM and LTM. However, doxorubicinol was only detectable in STM.  
Conclusion: STM is comparable to LTM to study relevant indices of cardiotoxicity of 
doxorubicin in rat hearts. Biochemical differences are more pronounced in STM, while 
contractile differences are more pronounced in LTM. STM could be a preferred model for 
preliminary studies of protective interventions.  
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Introduction 
The anthracycline doxorubicin is one of the most frequently prescribed anticancer drugs 
because of its activity in solid tumours as well as haematological malignancies. However, its 
pronounced cardiotoxicity limits long term use and prevents effective anticancer therapy.(1)  
A common approach to evaluating cardiac function is monitoring left ventricular ejection 
fraction. A weakness in this method is that cardiac damage is usually detected only when a 
functional impairment has already occurred, which leaves little room for early, preventive 
strategies.(2) Therefore, measurement of cardiospecific biomarkers can be a valid diagnostic 
tool for early identification, assessment, and monitoring of cardiotoxicity.(2) Cardiac 
troponins have been suggested as valuable biomarkers of anthracycline cardiotoxicity, both in 
animal and clinical studies.(3, 4) Furthermore, accumulation of reactive oxygen species 
(ROS), like hydrogenperoxide (H2O2) is associated with oxidative stress during myocardial 
injury. Thus, release of biomarkers like TnT and H2O2 are of relevance to study reduced 
cardiac function associated with doxorubicin, and should be supplemented by measurement of 
myocardial accumulation of the anthracycline and its metabolite doxorubicinol in 
experimental studies.  
Previous cardiotoxicity models include long term exposure to doxorubicin for 5-12 
weeks.(5-7) LTMs are time consuming, and represent long-time stress for the animals, and 
high mortality rates have been reported.(8, 9) Therefore, it is of interest to develop and test 
short-time models (STM) when studying cardiotoxicity of anthracyclines. A combination of 
in vivo and ex vivo animal models has the advantage that it includes relevant pharmacokinetic 
phases after administration of drugs in vivo. In addition, such a model allows controlled 
evaluation of relevant end points (cardiotoxicity) ex vivo, without interference of systemic 
effects. In this methodological study in rats we wanted to investigate if a STM model of 9 
days is comparable to a LTM of 9 weeks to study relevant indices of cardiotoxicity of 
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doxorubicin in hearts. Both models involved repetitive intraperitoneal injections of 
doxorubicin or saline in vivo, prior to evaluation of cardiotoxicity in ex vivo isolated 
Langendorff hearts. Previously described STMs have not studied the generation of free 
radicals and release of TnT, however, they have addressed physiological parameters 
describing reduction of cardiac function, and accumulation of doxorubicin in the 
myocard.(10, 11) Our STM model includes these important biomarkers, supplemented by 
measurement of doxorubicinol, and as such, is of interest to study protective interventions. 
Furthermore, the model allows switching between pressure and volume regulated flow, and 
the latter adds measurement of the resistance in the coronary vasculature induced by drug 
treatment.  
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Methods 
Materials  
Doxorubicin was purchased from Meda AS (Slemmestad, Norway), pentobarbital from 
Haukeland Hospital Pharmacy (Bergen, Norway), heparin from Leo Pharma A/S (Oslo, 
Norway), and ingredients for the Krebs-Henseleit bicarbonate buffer from Merck KGaA 
(Darmstadt, Germany). This study conforms to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996) and was approved by the Animal Care and User Committee in Norway. 
 
Animals  
Male Wistar rats (200 ± 2g) were purchased from Taconic (Ejby, Denmark). The animals 
were housed in grid-bottom metal wire cages in a room maintained at a 12 hour light/dark 
cycle at a temperature of 20-22ºC. They were acclimatised for 2 weeks, housed 3 per cage and 
allowed free access to food pellets (Pellets rodent, Special Diets Service, UK) and tap water 
until injection of doxorubicin or saline. The animals were separated in individual cages based 
on their respective treatments protocols.  
 
Langendorff perfusion model 
The perfusion medium was a modified, oxygenated (95% O2 and 5% CO2) Henseleit 
bicarbonate buffer (KHBB) (pH 7.4) containing in mM: 118.5 NaCl, 25.0 NaHCO3, 1.2 
MgS4, 4.7 KCl, 1.2 KH2PO4, 1.2 D-glucose and 1.25 CaCl2. Hearts were excised after 
anaesthesia of the rats with an i.p. injection of pentobarbital 50mg/kg (0.1ml/100g 
bodyweight) and heparinised i.p. (0.1ml 500IU/100g bodyweight). Anaesthesia was evaluated 
by the pedal-withdrawal reflex. The heart was rapidly excised and immediately placed in cold 
(4ºC) KHBB to temporarily stop its beating and preserve it from ischemic injury prior to 
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perfusion. The heart was mounted on a steel cannula placed in the aorta and perfused 
retrogradely in a Langendorff system with the use of thermostated (37ºC) Lauda reservoirs 
(Lauda-Königshofen, Germany), perfusion lines, and heart chamber. Pressure regulated flow 
was performed at 100cmH2O (73mmHg), while volume regulated flow (12.5ml/min) was 
performed by use of an Alitea peristaltic pump (Stockholm, Sweden). A water-filled latex 
balloon was placed in the left ventricle and connected to a SensoNor 840 pressure transducer 
(Memscap AS, Skoppum, Norway) for the recording of left ventricular developed pressure 
(LVDP) and secondarily derived contractility indices. Left ventricular end-diastolic pressure 
(LVEDP) was adjusted between 4 and 8mmHg. A second pressure transducer was connected 
to a side arm on the aortic cannula for the recording of aortic pressure (AoP), an index of 
coronary vascular resistance during volume-regulated perfusion. Pressure signals were 
amplified (Quadbridge, AD Instruments, London, UK) and recorded using a PowerLab data 
acquisition system (AD Instruments, East Sussex, England). AoP, LVDP, LVEDP and LVDP 
first derivatives maximum (dp/dtmax) and minimum (dp/dtmin) were continuously displayed 
and recorded. Pacing (300 beats per minute by electric stimulation of 5V amplitude of 3ms 
duration) was obtained by placing one electrode on the right auricle and one on the steel 
cannula. Coronary flow rate was measured by timed collection of the coronary perfusate that 
dripped from the heart. At the end of the perfusion protocol hearts were removed from the 
Langendorff system and myocardial tissue from the left ventricle was dissected free and 
immediately frozen in liquid helium and stored at -80ºC until analysis of doxorubicin and 
doxorubicinol, within 14 days of termination of the Langendorff protocol. Effluent samples of 
1mL were collected in 1.5mL polypropylene Eppendorf micro test tubes (Eppendorf Vertrieb, 
Wesseling-Berzdorf, Germany) from each heart, at the end of the perfusion protocol, and 
stored at 0ºC, until analysis for TnT within 4 days of termination of the Langendorff protocol. 
Effluent samples of 1mL were collected in Eppendorf tubes from each heart, at the end of the 
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perfusion protocol, and immediately analysed for H2O2, the samples were placed in a 
thermostated (37ºC) Eppendorf rack heated by a Lauda reservoir (Lauda-Königshofen, 
Germany). All experiments and analysis were carried out between 7am and 7pm. 
 
Experimental groups, drug treatments and Langendorff protocols (Figure I) 
Two protocols were tested: STM and LTM. Each protocol had an intervention group 
demarcated dox (doxorubicin) and a control group demarcated sal (saline). 
The intervention groups STMdox (n = 6) and LTMdox (n = 6) received an i.p. injection of 
2mg/kg doxorubicin every day on 5 consecutive days up to a total cumulative dose of 
10mg/kg doxorubicin.  
The control groups STMsal (n = 6) and LTMsal (n = 6): received an i.p. injection of 
equivalent volume 0.9% saline every day on 5 consecutive days.  
STM: On day 10, hearts from STMdox and STMsal were excised for the ex vivo experiments 
and Langendorff-perfused.  
LTM: After 9 weeks, hearts from LTMdox and LTMsal were excised for the ex vivo 
experiments and Langendorff-perfused.  
All hearts were subjected to the following perfusion protocol: A 15 minute stabilization 
period with pressure regulated flow, followed by 5 minutes with pressure regulated flow, and 
5 minutes with volume regulated flow. During the latter 10 minutes physiological data were 
recorded, and cardiac effluent samples collected for evaluation of biochemical and 
pharmacological parameters. The perfusion protocol is illustrated in Figure I. 
 
Determination of doxorubicin and doxorubicinol  
Doxorubicin and doxorubicinol were quantified by high performance liquid chromatography 
(HPLC-MS/MS) (1200 series RRLC, Agilent Technologies, USA) coupled to an Agilent 
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6410 triple quadrupole mass spectrometer using positive electrospray ionisation (Agilent 
Technologies, USA). Frozen left ventricular tissue was minced and weighted out in a glass 
tube with a screw cap and homogenized in physiological saline (2ml/100mg tissue) with a 
tissue homogenizer (Ultra Turrax, Sigma Aldrich, Germany). 1000µl of sample was added 
100µl of daunorubicin as internal standard (IS), and 200µl of buffer (1M TRIZMA, pH 11.1) 
and mixed well before extraction with 4ml ethylacetate/heptane (80/20 vol/vol). The samples 
were mixed using a rotary blender for 15 minutes and then centrifuged at 3500rpm for 10 
minutes at 10ºC. The organic phase was evaporated to dryness at 50ºC under nitrogen then 
dissolved in 100µl of methanol followed by 100µl of distilled water. The extract was mixed 
thoroughly and transferred to silanized vials before analysis. 25µl of extract was injected and 
separated on a Zorbax SB-Aq (2.1 x 50mm, 1.8µm particles, Agilent Technologies, USA) 
column using gradient elution with acetonitrile and 0.1% formic acid in water. Quantification 
were performed using multiple reaction monitoring (MRM) mode at m/z 546.1 → 363.1 for 
doxorubicinol, m/z 544.1 → 361.1 for doxorubicin and m/z 528.1 → 321.1 for daunorubicin 
(IS). 
 
Effluent content of TnT 
TnT in cardiac effluent was measured using an Elecsys 2010 immunoassay analyzer (Roche 
Diagnostics Norway AS, Oslo, Norway), based on the sandwich principle. Total duration of 
assay: 9 minutes. 1st incubation: 50µL of sample, a biotinylated monoclonal cardiac TnT-
specific antibody, and a monoclonal cardiac TnT-specific antibody labeled with a ruthenium 
complex (Tris(2,2-bipyridyl)ruthenium(II)-complex (Ru(bpy) )) reacted to form a sandwich 
complex. 2nd incubation: After addition of streptavidin-coated microparticles, the complex 
became bound to the solid phase via interaction of biotin and streptavidin. The reaction 
mixture was aspirated into the measuring cell where the microparticles were magnetically 
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captured onto the surface of the electrode. Unbound substances were then removed with 
ProCell. Application of a voltage to the electrode then induced chemiluminescent emission 
which was measured by a photomultiplier. Results were determined via a calibration curve 
which was instrument-specifically generated by 2-point calibration and a master curve (5-
point calibration) provided via the reagent barcode. Detection limit was 5.0ng/L   
 
Effluent content of H2O2 
H2O2 in cardiac effluent was measured using an Apollo 4000 electrochemical detection 
system (World Precision Instruments, Sarasota, Florida, USA). The electrode was calibrated 
using 9 serial dilutions of H2O2 in phosphate buffered saline with added aniline. The current 
recorded from the effluent was then calculated as µM H2O2. Samples were kept at 37°C 
during measurement. The electrode was allowed 3 minutes of stabilisation and 1 minute of 
recording.  
 
Statistics  
All results are reported as mean values ± standard deviation (SD) in tables. Groups were 
compared with regards to parameters with a student t-test. Only groups within similar 
protocols (STMdox with STMsal, and LTMdox with LTMsal) were compared. Differences 
between models were only described. SPSS for Windows version 17.0 was used, and p < 0.05 
was considered statistically significant.  
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Results 
H2O2 release in STMdox (77.4 ± 2.8µM) was significantly higher compared to H2O2 release 
in STMsal (12.8 ± 1.7µM). Similarly, H2O2 release in LTMdox (22.8 ± 5.3µM) was 
significantly higher compared to H2O2 release in LTMsal (9.9 ± 2.7µM). Myocardial content 
of doxorubicin and doxorubicinol in STMdox was 1.2 ± 0.18nmol/g and 0.45 ± 0.14nmol/g 
respectively. In LTMdox we found a doxorubicin content of 0.19 ± 0.02nmol/g. 
Doxorubicinol was undetectable after 9 weeks in LTMdox. TnT release was significantly 
higher in STMdox (345.3 ± 37.3ng/L) compared to STMsal (63.5 ± 9.7ng/L). Similarly, TnT 
release was significantly higher in LTMdox (152.2 ± 22.1ng/L) compared to LTMsal (48.0 ± 
14.8ng/L). In STM, hearts exposed to doxorubicin demonstrated a 15% reduction in left 
ventricular developed pressure (LVDP) irrespective of flow mode, and a 13% increase in 
aortic pressure (AoP), during volume regulated perfusion, an index of coronary resistance, 
compared to controls. Left ventricular end-diastolic pressure (LVEDP) was increased 72% 
during pressure regulated perfusion and 100% during volume regulated perfusion in STM. In 
LTM, hearts exposed to doxorubicin demonstrated a 40% reduction in LVDP during pressure 
regulated perfusion, and a 20% reduction during volume regulated perfusion. LVEDP was 
70% higher in doxorubicin treated hearts during pressure regulated perfusion and 80% higher 
during volume regulated perfusion. In addition, aortic pressure was increased 30% during 
volume regulated perfusion. In both STM and LTM, hearts exposed to doxorubicin 
demonstrated a higher H2O2 and TnT release, compared to respective controls. dp/dtmax was 
lower and dp/dtmin higher in STMdox and LTMdox compared to their respective controls, 
irrespective of perfusion mode. Coronary flow was decreased during pressure regulated 
perfusion, in the doxorubicin treated groups in both models, compared to controls.  All 
physiological results are presented in Table I and II and biochemical and pharmacological 
results in Table III and IV.  
 12 
Discussion 
Our study shows that a 9 day STM is sufficient time to demonstrate relevant indices of 
cardiotoxicity of doxorubicin in isolated Langendorff-perfused rat hearts, irrespective of flow 
mode. Our model allows parallel assessment of ROS and TnT release, myocardial content of 
anthracyclines and measurement of cardiac function. Biochemical differences are more 
pronounced in STM, while contractile differences are more pronounced in LTM. The latter 
reflects the accumulated myocardial contractile damage associated with doxorubicin in the 
tissue. However, STM represents a preferred model for preliminary preclinical studies of 
protective interventions with less stress for the animals, and at a lower cost.  
HPLC-MS/MS measurements of doxorubicin and its metabolite doxorubicinol showed 
significant accumulation of anthracyclines in the myocardial tissue. The results from the 
LTM, demonstrate the slow elimination of doxorubicin from myocardial tissue. Disposition of 
doxorubicinol in patients is formation rate limited, with the terminal half-life of the metabolite 
being similar to doxorubicin. The relative exposure of doxorubicinol, i.e., the ratio between 
area under the curve (AUC) for doxorubicinol compared to AUC for doxorubicin ranges 
between 0.3 and 0.6.(12, 13) Thus, doxorubicinol is present in a much lower concentration 
than doxorubicin, though it is proposed to be more toxic compared with doxorubicin, and it 
has been established that doxorubicinol is nearly 30 times more potent than doxorubicin at 
inhibiting calcium-handling proteins and at depressing contractility and systolic myocardial 
function.(14, 15)  
We used a 3rd generation troponin T test, Elecsys 2010 immunoassay analyser. This 
test uses the same monoclonal antibodies (M11.7 and M7) as the 2nd generation ES 300 test, 
but is standardized with human recombinant cardiac TnT instead of bovine cardiac TnT, 
which has been used previously. However, previous studies(16) have concluded that there 
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were no differences in coronary TnT concentrations in isolated rat heart effluent between 2nd 
and 3rd generation cardiac TnT assays, ES 300 and Elecsys 2010, respectively.  
In our STM, a significant reduction in contractile parameters due to anthracyclines 
could be studied in Langendorff hearts irrespective of flow mode. Reduction of cardiac 
function can be directly related to measurements of myocardial release of relevant biomarkers 
and content of doxorubicin and doxorubicinol. With volume regulated flow, the effects on 
coronary vascular resistance of the anthracycline can be studied in parallel with effects on 
myocardial contractility. Thus, reduced contractility as a result of reduced coronary flow 
during pressure regulated perfusion could be assessed. Our results demonstrate that flow 
mode is of minor importance when studying myocardial effects of doxorubicin in this model.  
In our STM, LVDP in doxorubicin treated rats were significantly reduced compared to 
controls both during pressure regulated and volume regulated perfusion. A similar short term 
model found comparable results (17), they studied cardiac performances of ex vivo perfused 
hearts from rats that had been treated with various anthracyclines within 12 days, 
administrated by repetitive injections. One group received 3mg/kg doxorubicin every other 
day for 12 days, up to a total cumulative dose of 18mg/kg. Even though they used a higher 
total cumulative dose compared to our study, they found that their model was able to predict 
correctly what was already known concerning the cardiotoxicity of anthracyclines. These 
findings support our STM.  
Different laboratories use different doses of doxorubicin to induce cardiotoxicity. In 
general, i.p. injections of 2.0-4.0mg/kg are used, up to total cumulative doses of 10-20mg/kg, 
but higher doses have been reported. In our study, we used 2mg/kg doxorubicin, up to a total 
cumulative dose of 10mg/kg, to induce cardiotoxicity. Selection of dose and concentration of 
doxorubicin was done to give the rats a total cumulative dose high enough to induce 
myocardial damage, but at the same time low enough to keep them alive. Choice of dose is 
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particularly important to reduce the possibility of masking beneficial effects of protective 
interventions. In our results, a reduction of 15% of LVDP compared to controls in STM 
provides frame for evaluating such effects, and an increase in dose is possible. The dosage 
and concentration frame of doxorubicin used in this study has been applied in previous 
studies, and has yielded comparable results.(11, 17, 18)  
  Reduction of the cardiotoxicity of doxorubicin and its main metabolite doxorubicinol, 
while retaining their anticancer effect, is desirable. Thus, interventions that reduce 
accumulation of anthracyclines and improve the drug’s effect on cardiac function can be 
measured directly in our STM. Interestingly, diastolic dysfunction, reflecting poor ventricular 
compliance, is reported to be an early sign of anthracycline cardiotoxicity in the clinic.(19, 
20) Diastolic dysfunction and increased coronary vascular resistance was observed both in 
STM and LTM in the present results, and flow mode did not influence the results. 
Interestingly, an increase of LVEDP between 70-100% was apparent already in our 9 day 
model and was still present after 9 weeks. However, the increase in coronary vascular 
resistance was doubled in the same period from 13-30%. Thus, long time effects of 
doxorubicin in the heart, affect both cardiomyocytes and the coronary arteries. 
Finally, use of pacing gave us the opportunity to study contractile indices without 
interference of arrhythmias associated with anthracyclines.(21) Thus, our STM seems robust 
and reproducible, and it should be possible to add new indices of cardiotoxicity into this 
model in future studies.  
 
Limitations 
The present STM is suitable for preclinical evaluation of new protective interventions to 
reduce anthracycline cardiotoxicity. However, protection in compressed doxorubicin 
regimens is not necessarily equiprotective when tested in a more clinically relevant chronic 
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regimens. Such studies should be reserved for interventions proven effective and safe in STM. 
Furthermore, the model allows the possibility to elucidate important pathways associated with 
cardioprotective principles.    
Repeated i.p. injections could give development of scar tissue and thickened skin with 
reduced and unpredictable absorption of drugs. Furthermore, doxorubicin could give local 
tissue damage and inflammation. We were careful to alternate injection sites, using correct 
injection techniques including a suitable needle to reduce this problem. The compartmental 
distribution of doxorubicin in the myocardium or within cardiomyocytes is not known due to 
the fact that heart tissue was minced and homogenized. Precise cellular and subcellular 
distribution of the anthracycline is of relevance to understand mechanisms of cardiotoxicity.  
Assessment of effect on cardiomyopathy is important in studies of anthracyclines. In our 
study, the condition of the heart at the two time points would be of interest. However, our 
model did not allow for cardiac pathology due to the tissue being used to detect doxorubicin 
and doxorubicinol.   
 We used cardiac pacing, which excludes the possibility of evaluating heart rate and 
electrocardiograms. This would have been valuable and interesting information considering 
the well-known association between arrhythmias and anthracyclines. However, assessment of 
cardiac function (recording of left ventricular developed pressure (LVDP) and secondarily 
derived contractility indices) was of particular importance in this study, and pacing was used 
to obtain optimal recordings not influenced by arrhythmias. 
An experimental STM with a combination of in vivo doxorubicin administration and 
subsequent ex vivo evaluation of cardiotoxicity in the rat must make some compromises in 
comparison to the clinical administration of the drug. The development of cardiotoxicity in 
animal models with weekly injections is previously described in the literature.(17) Repetitive 
low doses are preferred compared to a single high dose in the rat, and every-other-day 
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administration has been proposed.(22) In our STM we used daily i.p. injections to reduce 
duration of the experiments. 
Non-invasive transthoracic echocardiography is suitable for studying development and 
course of anthracyclines cardiomyopathy, and development of heart failure in animal 
models.(23)  Our global isovolumetric STM cannot reflect in vivo heart function, and 
reduction of contractile indices represents only indirect measures of heart failure. However, 
our STM is ideal to study contractile function in parallel with release of relevant biochemical 
parameters in real time specific to the heart. Release of biomarkers in blood associated with in 
vivo models could be subject to several systemic effects and be less specific to the organ of 
interest.  
Our STM does not allow measurement of intracellular production and compartmental 
distribution and release of H2O2. Thus, release in effluate represents a sum of venous drain 
(majority) and exudate from the surface of the heart (minority) from the organ. After nine 
weeks, pathological changes in the heart could allow for a different distribution and release of 
H2O2. However, release is specific to the organ compared to in vivo models where 
development of heart failure would affect potential release from other organs.  
 
Conclusion 
STM is comparable to LTM to study relevant indices of cardiotoxicity of doxorubicin in rat 
hearts. Thus, STM could be a preferred model for further studies of protective interventions.  
STM is a better alternative than previously described LTMs, because it submits the animals to 
less stress and discomfort. In addition a STM is less time consuming, more cost effective and 
more in accordance with the idea of refinement for use of laboratory animals. This study 
shows that our STM is a promising alternative for future preclinical studies of cardiotoxic 
mechanisms of doxorubicin and doxorubicinol, and for studies of protective interventions.  
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Table I  
Physiological results from hearts in the short-time model during pressure and volume 
regulated perfusion 
STM Pressure regulated perfusion Volume regulated perfusion 
 STMdox  n = 6 
2mg/kg doxorubicin 
STMsal  n = 6 
Saline injection 
STMdox  n = 6 
2mg/kg doxorubicin 
STMsal  n = 6 
Saline injection 
LVDP (mmHg)  112.1 ± 7.6 * 130.9 ± 4.4 130.3 ± 6.9 * 150.4 ± 2.4 
LVEDP (mmHg) 14.8 ± 3.1 *  8.6 ± 0.7 21.9 ± 2.3 * 10.7 ± 2.9 
AoP (mmHg) 73.0 ± 0 73.0 ± 0 144.8 ± 0.5 * 127.5 ± 10.5 
Heart rate (beats per minute) 300 ± 0  300 ± 0 300 ± 0 300 ± 0 
dp/dt max (mmHg/s) 3490.2 ± 448.9 *  4064.8 ± 201.3 2955.9 ± 362.2 * 4184.6 ± 202.8 
dp/dt min (mmHg/s) -1870.8 ± 153.8 * -2362.5 ± 190.8 -1266.1 ± 503.2 * -2514.9 ± 65.5 
Coronary flow (ml/min) 8.1 ± 0.5 * 11.1 ± 0.6 12.5 ± 0 12.5 ± 0 
Table I Values presented as mean ± standard deviation (SD). * = significantly different from control hearts, 
p<0.05. Short time model doxorubicin treated hearts (STMdox). Short time model saline treated hearts 
(STMsal). Left ventricular developed pressure (LVDP). Left ventricular end diastolic pressure (LVEDP). Aortic 
pressure (AoP).  
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Table II  
Physiological results from hearts in the long-time model during pressure and volume 
regulated perfusion 
LTM Pressure regulated perfusion Volume regulated perfusion 
 LTMdox  n = 6 
2mg/kg doxorubicin 
LTMsal  n = 6 
Saline injection 
LTMdox  n = 6 
2mg/kg doxorubicin 
LTMsal  n = 6 
Saline injection 
LVDP (mmHg) 64.1 ± 3.9 * 106.9 ± 7.5 95.8 ± 17.3 * 119.2 ± 8.1 
LVEDP (mmHg) 11.4 ± 1.7 * 6.7 ± 1.5 12.9 ± 0.8 * 7.1 ± 0.8 
AoP (mmHg) 73.0 ± 0 73.0 ± 0 130.6 ± 4.7 * 97.2 ± 8.8 
Heart rate (beats per minute) 300 ± 0 300 ± 0 300 ± 0 300 ± 0 
dp/dt max (mmHg/s) 1667.2 ± 299.6 * 3099.2 ± 202.6 2707.6 ± 298.7 * 4413.9 ± 488.2 
dp/dt min (mmHg/s) -834.2 ± 98.9 * -2137 ± 285.7 -1235.1 ± 320.1 * -2568.0 ± 186.2 
Coronary flow (ml/min) 6.3 ± 0.9 * 11.9 ± 0.6 12.5 ± 0 12.5 ± 0 
Table II Values presented as mean ± standard deviation (SD). * = significantly different from control hearts, 
p<0.05. Long time model doxorubicin treated hearts (LTMdox). Long time model saline treated hearts 
(LTMsal). Left ventricular developed pressure (LVDP). Left ventricular end diastolic pressure (LVEDP). Aortic 
pressure (AoP).  
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Table III  
Biochemical and pharmacological results from hearts in the short-time model  
 
STM STMdox 
2mg/kg doxorubicin 
STMsal 
Saline injection 
Doxorubicin  
tissue concentration (nmol/g) 
1.2 ± 0.18  0 ± 0 
Doxorubicinol  
tissue concentration (nmol/g) 
0.45 ± 0.14  0 ± 0 
Troponin -T effluate 
concentration (ng/L) 
345.3 ± 37.3 * 63.5 ± 9.7 
H2O2 effluate concentration 
(µM) 
77.4 ± 2.8 * 12.8 ± 1.7 
Table III Values presented as mean ± standard deviation (SD). * = significantly different from controls, p<0.05. 
Short time model doxorubicin treated hearts (STMdox). Short time model saline treated hearts (STMsal). 
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Table IV  
Biochemical and pharmacological results from hearts in the long-time model  
 
LTM LTMdox  
2mg/kg doxorubicin 
LTMsal  
Saline injection 
Doxorubicin  
tissue concentration (nmol/g) 
0.19 ±  0.02  0 ± 0  
Doxorubicinol  
tissue concentration (nmol/g) 
0 ± 0 0 ± 0 
Troponin -T effluate 
concentration (ng/L) 
152.2 ± 22.1 * 48.0 ± 14.8  
H2O2 effluate concentration 
(µM) 
22.8 ± 5.3 * 9.9 ± 2.7 
Table IV Values presented as mean ± standard deviation (SD). * = significantly different from controls, p<0.05. 
Long time model doxorubicin treated hearts (LTMdox). Long time model saline treated hearts (LTMsal). 
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Figure I Perfusion protocols 
 
 
Figure 1. Short time model doxorubicin treated hearts (STMdox). Short time model saline treated hearts 
(STMsal). Long time model doxorubicin treated hearts (LTMdox). Long time model saline treated hearts 
(LTMsal). 
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